DENALI THERAPEUTICS INC (DNLI)

US24823R1059 - Common Stock

19.1  -2.15 (-10.12%)

After market: 19.13 +0.03 (+0.16%)

Fundamental Rating

3

DNLI gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. DNLI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, DNLI is valued expensive at the moment.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

DNLI had negative earnings in the past year.
DNLI had a negative operating cash flow in the past year.
In the past 5 years DNLI reported 4 times negative net income.
DNLI had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

DNLI has a better Return On Assets (-29.40%) than 69.55% of its industry peers.
Looking at the Return On Equity, with a value of -32.42%, DNLI is in the better half of the industry, outperforming 77.66% of the companies in the same industry.
Industry RankSector Rank
ROA -29.4%
ROE -32.42%
ROIC N/A
ROA(3y)-18.54%
ROA(5y)-17.38%
ROE(3y)-25.19%
ROE(5y)-23.88%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

DNLI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

6

2. Health

2.1 Basic Checks

DNLI does not have a ROIC to compare to the WACC, probably because it is not profitable.
DNLI has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, DNLI has more shares outstanding
There is no outstanding debt for DNLI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

DNLI has an Altman-Z score of 11.67. This indicates that DNLI is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of DNLI (11.67) is better than 87.39% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that DNLI is not too dependend on debt financing.
DNLI has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 11.67
ROIC/WACCN/A
WACC10.68%

2.3 Liquidity

A Current Ratio of 9.98 indicates that DNLI has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 9.98, DNLI belongs to the top of the industry, outperforming 80.54% of the companies in the same industry.
A Quick Ratio of 9.98 indicates that DNLI has no problem at all paying its short term obligations.
DNLI has a Quick ratio of 9.98. This is amongst the best in the industry. DNLI outperforms 80.90% of its industry peers.
Industry RankSector Rank
Current Ratio 9.98
Quick Ratio 9.98

More info and screens

5

3. Growth

3.1 Past

The earnings per share for DNLI have decreased strongly by -194.85% in the last year.
The Revenue for DNLI has decreased by -100.00% in the past year. This is quite bad
Measured over the past years, DNLI shows a very strong growth in Revenue. The Revenue has been growing by 20.67% on average per year.
EPS 1Y (TTM)-194.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-0.52%
Revenue growth 5Y20.67%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, DNLI will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.14% on average per year.
The Revenue is expected to grow by 15.15% on average over the next years. This is quite good.
EPS Next Y-163.64%
EPS Next 2Y-66.45%
EPS Next 3Y-29.87%
EPS Next 5Y14.14%
Revenue Next Year-96.88%
Revenue Next 2Y-59.72%
Revenue Next 3Y-17.71%
Revenue Next 5Y15.15%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DNLI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DNLI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

DNLI's earnings are expected to decrease with -29.87% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-66.45%
EPS Next 3Y-29.87%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DNLI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DENALI THERAPEUTICS INC

NASDAQ:DNLI (1/10/2025, 8:13:08 PM)

After market: 19.13 +0.03 (+0.16%)

19.1

-2.15 (-10.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Inst Owners90.44%
Inst Owner Change0%
Ins Owners4.57%
Ins Owner Change-0.57%
Market Cap2.75B
Analysts86.36
Price Target43.62 (128.38%)
Short Float %5.74%
Short Ratio8.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.55%
Min EPS beat(2)-0.5%
Max EPS beat(2)15.61%
EPS beat(4)1
Avg EPS beat(4)0.37%
Min EPS beat(4)-8.8%
Max EPS beat(4)15.61%
EPS beat(8)4
Avg EPS beat(8)36.93%
EPS beat(12)5
Avg EPS beat(12)21.54%
EPS beat(16)6
Avg EPS beat(16)1506.22%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)2
Avg Revenue beat(8)193.84%
Revenue beat(12)4
Avg Revenue beat(12)123.36%
Revenue beat(16)5
Avg Revenue beat(16)99.97%
PT rev (1m)2.58%
PT rev (3m)6.92%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-18.7%
EPS NY rev (1m)-1.53%
EPS NY rev (3m)-10.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-22.41%
Revenue NY rev (1m)19.06%
Revenue NY rev (3m)-51.1%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.08
P/tB 2.08
EV/EBITDA N/A
EPS(TTM)-2.86
EYN/A
EPS(NY)-2.99
Fwd EYN/A
FCF(TTM)-2.61
FCFYN/A
OCF(TTM)-2.52
OCFYN/A
SpS0
BVpS9.16
TBVpS9.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.4%
ROE -32.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-18.54%
ROA(5y)-17.38%
ROE(3y)-25.19%
ROE(5y)-23.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 151.87%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.98
Quick Ratio 9.98
Altman-Z 11.67
F-Score1
WACC10.68%
ROIC/WACCN/A
Cap/Depr(3y)115.78%
Cap/Depr(5y)121.51%
Cap/Sales(3y)12.59%
Cap/Sales(5y)21.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-194.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
EPS Next Y-163.64%
EPS Next 2Y-66.45%
EPS Next 3Y-29.87%
EPS Next 5Y14.14%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-0.52%
Revenue growth 5Y20.67%
Sales Q2Q%-100%
Revenue Next Year-96.88%
Revenue Next 2Y-59.72%
Revenue Next 3Y-17.71%
Revenue Next 5Y15.15%
EBIT growth 1Y-197.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-189.52%
EBIT Next 3Y-33.53%
EBIT Next 5Y12.36%
FCF growth 1Y-48.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-52.64%
OCF growth 3YN/A
OCF growth 5YN/A